Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso

Authors

  • Serge Theophile Soubeiga Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Bapio Valéry Jean Telesphore Elvira Bazie Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Tegwindé Rebeca Compaore Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Abdoul Karim Ouattara Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Théodora Mahoukèdè Zohoncon Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Dorcas Obiri-Yeboah Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast
  • Albert Théophane Yonli Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Arsène Zongo Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Lassina Traore Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Virginio Pietra Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo
  • Simon Akpona University of Parakou
  • Serge Diagbouga Research Institute for Health Sciences, Ouagadougou
  • Jacques Simpore Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo

DOI:

https://doi.org/10.4081/jphia.2018.767

Keywords:

HIV-1 drug resistance, ART, MTCT, Burkina Faso

Abstract

The emergence of HIV-1 drug resistance (HIVDR) is a public health problem that affects women and children. Local data of HIVDR is critical to improving their care and treatment. So, we investigated HIVDR in mothers and infants receiving antiretroviral therapy (ART) at Saint Camille Hospital of Ouagadougou, Burkina Faso. This study included 50 mothers and 50 infants on ART. CD4 and HIV-1 viral load were determined using FACSCount and Abbott m2000rt respectively. HIVDR was determined in patients with virologic failure using ViroSeq HIV-1 Genotyping System kit on the 3130 Genetic Analyzer. The median age was 37.28 years in mothers and 1.58 year in infants. Sequencing of samples showed subtypes CRF02_AG (55.56%), CRF06_cpx (33.33%) and G (11.11%). M184V was the most frequent and was associated with highlevel resistance to 3TC, FTC, and ABC. Other mutations such as T215F/Y, D67N/E, K70R, and K219Q were associated with intermediate resistance to TDF, AZT, and 3TC. No mutation to LPV/r was detected among mothers and infants. The findings of HIVDR in some mothers and infants suggested the change of treatment for these persons.

Download data is not yet available.

Downloads

Published

06-07-2018

How to Cite

Soubeiga, S. T., Bazie, B. V. J. T. E., Compaore, T. R., Ouattara, A. K., Zohoncon, T. M., Obiri-Yeboah, D., Yonli, A. T., Zongo, A., Traore, L., Pietra, V., Akpona, S., Diagbouga, S., & Simpore, J. (2018). Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso. Journal of Public Health in Africa, 9(1). https://doi.org/10.4081/jphia.2018.767

Issue

Section

Original Articles